Merck Opens M Lab Collaboration Center in Shanghai
16th July 2020
Germany’s Merck has opened its latest M Lab collaborative drug development center in Shanghai, China. With lab space of around 10,000 m2, the facility is the largest of the pharmaceutical, chemicals and life science group’s nine such centers worldwide and is located in the heart of Shanghai’s biomedical sciences and research community.
According to Merck, its concept provides customizable solutions to help advance drug development, including pilot scale and process development support labs that offer non-GMP space.
In the labs, customers can explore ideas, learn innovative techniques and work side-by-side with the German company’s scientists and engineers on problem solving and also participate in hands-on training, formal bioprocessing educational courses and experiments.
With a digital platform that improves efficiency and processes by automating workflows and connecting lab instruments via the cloud, the Shanghai center also focuses on lab management software.
A customized cell culture media facility designed to develop cell culture media that can be used to produce biopharmaceuticals and for non-GMP pilot production is also part of the center.
Separately, a solid dose formulation facility is available to test whether drugs in tablet, capsule or powder form contain high quality excipients and active pharmaceutical ingredients (APIs), while a new end-to-end solutions GMP manufacturing facility will be able to offer CDMO services to Merck’s customers in China and Asia Pacific.
Vaccine makers are increasingly looking for CDMOs that have the capability to quickly provide the needed manufacturing capability for vaccines against Covid-19 that are currently under development.
Merck is currently working with more than 200 groups developing Covid-19 vaccines and drugs, including the UK’s Oxford University and Baylor University and Oxford University in the US state of Texas.
For more information visit www.chemanager-online.com/en